Structured market prediction extracted from social analysis, normalized by AI, enriched with validation metrics, analyst reliability, live position tracking and source-level evidence.
Entry, target and invalidation logic
The original analyst prediction is converted into a structured intelligence object with price mentions, normalized direction, target distance, invalidation distance and risk/reward context.
AI quality scoring
Each signal is scored for clarity, accuracy, actionability and overall usefulness before it contributes to intelligence metrics.
What happened after publication?
The platform tracks price movement after publication and records outcome, runup, drawdown and resolution metadata.
Who generated this prediction?
Source, summary and reference
The video provides a fundamental analysis of three stocks: PayPal (PYPL), Bristol-Myers Squibb (BMY), and Target (TGT).For PYPL, the analysis notes a 61% decline over five years, indicating a long base formation, and growing active accounts. Despite revenue growth deceleration, it's accelerating. With $7B in free cash flow and significant share buybacks, the analyst infers a target price of $100. The analysis will be invalidated at $60.BMY trades at seven times earnings with a sustainable dividend yield. Despite impending patent expirations, the video highlights BMY’s strategy of acquiring new drugs to maintain free cash flow. It is assigned a target of $60 and fail price of $40.Target's comp sales have been negative and depend greatly on discretionary expenditures, resulting in a negative outlook. The analysis will be invalidated at a price of $95, with an inferred target of $70.
Friends! In this video, I'm going to do an analysis on Paypal stock, BMY stock and TGT stock MY PORTFOLIO & DISCORD: https://www.patreon.com/patientinvestor MY TWITTER: https://twitter.com/patientinvestt 0:00 First stock 7:08 2nd stock 11:24 3rd stock FREE ACCESS To Fiscal.AI https://fiscal.ai/?via=Patient
Scoring and consensus eligibility
These fields explain whether this prediction is already verified, whether it contributes to analyst scoring, and whether it is included in symbol target consensus.